Sanofi is here to support you and your patients.
Ask us your questions about our products, patient materials or organising a meeting.
Edition Junior
Download this clinical summary to read about the benefits of Toujeo® in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL from baseline to Week 26.
Toujeo
Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.
Patient Website
Find resources and support for your patients on Toujeo®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.
MAT-XU-2205630 (v4.0)
Date of Preparation: September 2023
